I appreciate your ability to refocus the discussio
Post# of 148292
Regarding our data - the CD10 data is better than other drugs that have received EUAs. Which leads me to wonder who in the FDA we are taking guidance from versus who is approving EUAs. I am not big on bashing the FDA, but the ability to get to the real decision makers is likely a weakness for smaller drug companies. That said, I agree with you that at this point we need strong CD12 data. Period.